The pharmaceuticals industry in the US focuses on research, development, manufacturing, and marketing of medications. Companies range from giant corporations like Pfizer to innovative biotech startups creating specialized therapies. This vital sector not only addresses public health needs with life-saving drugs and treatments but also significantly shapes the economy, with substantial investments in research and development. As technology integrates more into healthcare, trends such as personalized medicine and digital health solutions are transforming patient care. With a robust regulatory framework supporting advancements, the future promises continued growth driven by innovation and an increasing emphasis on patient outcomes.

The listed pharmaceuticals investors vary in type, with venture capital firms and corporations among them. Headquartered primarily in major cities like New York and Boston, their sizes range from small firms with fewer than 50 employees to large entities with thousands on their payrolls. Founded from 1849 to 2017, many of these investors made significant contributions in 2024, participating in numerous funding rounds. This assortment indicates a rich environment for capital deployment in pharmaceuticals, reflecting both the urgency for groundbreaking healthcare solutions and a thriving investor appetite for innovation.

Top 19 Pharmaceuticals Investors in the US

1. OrbiMed

• Website: orbimed.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1989
• Headcount: 51-200
• Number of deals in 2024: 52
• LinkedIn: orbimed-advisors

OrbiMed is an investment firm based in New York, specializing in healthcare investments. Founded in 1989, the firm manages approximately $17 billion in assets across various investment strategies, focusing on biopharmaceuticals, medical devices, and healthcare services. OrbiMed has been actively involved in the pharmaceuticals sector, with notable transactions including multiple funding rounds for Acceleron Pharma, where they participated in Series B, C, and a venture round, totaling over $100 million. Additionally, they invested in Sierra Oncology during its Series D round, raising $59.5 million. Their recent involvement in Insmed's post-IPO debt round, amounting to $500 million, further underscores their commitment to supporting pharmaceutical companies. OrbiMed's clients include medical institutions and investment funds, all seeking to drive innovation in the healthcare sector.

2. Y Combinator

• Website: ycombinator.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2005
• Headcount: 51-200
• Number of deals in 2024: 802
• LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies through a structured program that includes resources like the Startup School and co-founder matching services. Over the years, Y Combinator has successfully launched more than 4,000 startups, establishing itself as a key player in the technology startup ecosystem. Among its diverse portfolio, Y Combinator has made notable investments in the pharmaceuticals sector, including Sterna Biologicals, which raised an undisclosed amount in a venture round in August 2022, and SFA Therapeutics, which secured $125,000 in a seed round in August 2021. Additionally, Y Combinator participated in a $10 million Series A financing round for Shasqi, Inc., which is focused on GMP manufacturing and supporting a Phase 1 human trial. These transactions highlight Y Combinator's engagement in the pharmaceuticals industry, despite its broader focus on technology startups.

3. Perceptive Advisors

• Website: perceptivelife.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1999
• Headcount: 11-50
• Number of deals in 2024: 45
• LinkedIn: perceptive-advisors-llc

Perceptive Advisors is a New York-based investment firm founded in 1999, specializing in the life sciences sector. The firm provides capital solutions and investment management services to both private and public healthcare companies, with a particular focus on biotechnology, pharmaceuticals, and medical devices. Their expertise in the healthcare industry enables them to support innovation and growth effectively. Notable transactions include a $42 million Series B investment in Cidara Therapeutics, which focuses on developing therapeutics for infectious diseases, and a $143 million Series B investment in CinCor Pharma, aimed at advancing treatments for hypertension and chronic kidney disease. Additionally, they participated in a $130 million equity financing round for Prometheus Biosciences, which is involved in developing precision medicine for autoimmune diseases. These transactions highlight Perceptive Advisors' commitment to advancing pharmaceutical innovations.

4. New Enterprise Associates (NEA)

• Website: nea.com
• Type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Founded year: 1977
• Headcount: 51-200
• Number of deals in 2024: 57
• LinkedIn: new-enterprise-associates

New Enterprise Associates (NEA) is a venture capital firm founded in 1977, based in Menlo Park, California. NEA specializes in investment management and advisory services for startups, particularly in the technology and healthcare sectors. The firm partners with entrepreneurs to provide funding and strategic guidance, helping them navigate the challenges of building successful businesses. NEA operates through a collaborative approach, emphasizing long-term relationships with founders. In the pharmaceuticals context, NEA has been involved in notable transactions such as their participation in multiple funding rounds for Amplyx Pharmaceuticals, including a $67 million Series C round in 2017 and a $40.5 million Series B round in 2015. Additionally, they were part of the $27.5 million Series A round for Supernus Pharmaceuticals in 2006. These investments highlight NEA's active engagement in the pharmaceuticals industry, making them a relevant player in this sector.

5. MedTech Innovator

• Website: medtechinnovator.org
• Type: Corporate
• Headquarters: Los Angeles, California, United States (USA)
• Founded year: 2013
• Headcount: 11-50
• Number of deals in 2024: 85
• LinkedIn: medtech-innovator

MedTech Innovator is a not-for-profit organization based in Los Angeles, California, founded in 2013. It serves as the largest accelerator for medical technology companies, providing accelerator programs, mentorship, and competitions to support startups in the medical device, digital health, and diagnostics sectors. In 2024, they have made 85 investments, showcasing their active role in the healthcare innovation landscape. Notably, they have been involved in transactions such as PHARMAJET, which raised over $3 million in Series F funding, focusing on drug delivery technologies. Other relevant transactions include ZetaGen Therapeutics and PanTher Therapeutics, which are also aligned with pharmaceutical advancements. These activities highlight MedTech Innovator's significant role in supporting innovations that intersect with the pharmaceuticals industry.

6. Pfizer

• Website: pfizer.com
• Type: Corporate
• Headquarters: New York, New York, United States (USA)
• Founded year: 1849
• Headcount: 10001+
• Number of deals in 2024: 10
• LinkedIn: pfizer

Pfizer Inc. is a prominent pharmaceutical and biotechnology company founded in 1849, headquartered in New York, New York, USA. With over 10,000 employees, Pfizer develops and produces a diverse range of medicines and vaccines aimed at improving patient health outcomes globally. The company has been actively investing in the pharmaceuticals sector, as evidenced by its recent transactions. In December 2021, Pfizer acquired Arena Pharmaceuticals for $6.7 billion, enhancing its portfolio in the treatment of various diseases. In March 2023, Pfizer announced a planned acquisition of Seagen, aiming to raise $31 billion through a debt offering to finance this significant move. Additionally, Pfizer has made strategic investments in companies like Amplyx Pharmaceuticals, focusing on therapies for invasive fungal infections, and CytomX Therapeutics, which is advancing Probody therapeutics. These transactions highlight Pfizer's ongoing commitment to innovation and growth within the pharmaceuticals industry.

7. Sosv

• Website: sosv.com
• Type: Venture Capital
• Headquarters: United States (USA)
• Founded year: 1995
• Headcount: 51-200
• Number of deals in 2024: 170
• LinkedIn: sosv

SOSV is a venture capital firm founded in 1995, based in the United States, that specializes in funding and supporting deep tech startups through its development programs. With a focus on health and climate technology, SOSV provides venture capital investment and resources to help startups grow and succeed. Notably, they have been involved in several transactions within the pharmaceuticals sector, including multiple seed rounds and convertible notes for Pannex Therapeutics Inc. in 2021 and 2022, as well as a convertible note for A2A Pharmaceuticals in 2016. These investments highlight SOSV's active role in fostering innovation in the pharmaceutical industry, connecting innovative companies with investors globally.

8. ARCH Venture Partners

• Website: archventure.com
• Type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Founded year: 1986
• Headcount: 11-50
• Number of deals in 2024: 32
• LinkedIn: arch-venture-partners

ARCH Venture Partners is a venture capital firm based in Chicago, Illinois, founded in 1986. The firm specializes in biotechnology investments, providing funding and strategic support to innovative companies in the life sciences sector. They primarily focus on early-stage biotech firms that are developing groundbreaking medical solutions. Notable transactions include significant investments in Vir Biotechnology, which raised $327.6 million in a Series B round in 2019 and $150 million in a venture round in 2017, both aimed at advancing their work in infectious diseases. Additionally, ARCH has invested in Achaogen, which is focused on developing novel antibiotics to combat multi-drug resistant bacteria, highlighting their commitment to pharmaceuticals. Their involvement in these transactions underscores their active role in the pharmaceuticals industry.

9. Frazier Healthcare Partners

• Website: frazierhealthcare.com
• Type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Founded year: 1991
• Headcount: 51-200
• Number of deals in 2024: 27
• LinkedIn: frazier-healthcare-partners

Frazier Healthcare Partners is a Seattle-based venture capital firm founded in 1991, specializing in healthcare and life sciences investments. The firm focuses on growth buyout investments in profitable healthcare businesses and innovative biopharmaceuticals. Notable transactions include a $59.5 million Series D investment in Sierra Oncology, a $42 million Series B investment in Cidara Therapeutics, and a $60.1 million Series C investment in Portola Pharmaceuticals. These investments highlight Frazier's active role in supporting the development of new pharmaceutical therapies and their commitment to advancing healthcare innovation.

10. Vivo Capital

• Website: vivocapital.com
• Type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Founded year: 1996
• Headcount: 51-200
• Number of deals in 2024: 19
• LinkedIn: vivo-capital

Vivo Capital is an investment firm founded in 1996, based in Palo Alto, California, specializing in healthcare. The firm provides venture capital, private equity, and public equity investments to healthcare companies, facilitating innovation and growth in the sector. Vivo Capital has been actively involved in the pharmaceuticals industry, participating in notable transactions such as Bristol-Myers Squibb's $80 million post-IPO equity raise in 2017, and Sierra Oncology's $59.5 million Series D funding in 2014. More recently, they participated in significant post-IPO equity transactions for Cidara Therapeutics and Aclaris Therapeutics, raising $105 million and $80 million respectively in November 2024. Their focus on companies that develop healthcare technologies and products positions them as a key player in the pharmaceuticals investment landscape.

11. Invus

• Website: invus.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1985
• Headcount: 51-200
• Number of deals in 2024: 35
• LinkedIn: invus

Invus is an investment firm based in New York, specializing in equity investments and investment management since its founding in 1985. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value, focusing on long-term growth. Invus has been involved in several notable transactions within the pharmaceuticals sector, including significant investments in Lexicon Pharmaceuticals, where they participated in multiple rounds of post-IPO equity funding totaling over $300 million. They also co-led a $93 million Series B financing round for Oyster Point Pharmaceuticals, aimed at developing treatments for Dry Eye Disease. Furthermore, Invus was part of the largest private fundraising round for Moderna Therapeutics, showcasing their active role in supporting innovative biotechnology companies. This diverse portfolio highlights Invus's capability and commitment to fostering growth in the pharmaceuticals industry while maintaining a broader investment strategy.

12. Janus Henderson Investors

• Website: janushenderson.com
• Type: Private Equity
• Headquarters: Denver, Colorado, United States (USA)
• Founded year: 2017
• Headcount: 1001-5000
• Number of deals in 2024: 39
• LinkedIn: janus-henderson-emea

Janus Henderson Investors is an asset management firm based in Denver, Colorado, with a global presence and a focus on providing a range of investment products including ETFs, mutual funds, and managed accounts. Founded in 2017, the firm serves individual investors, financial professionals, and institutional clients, aiming to achieve superior financial outcomes through disciplined investment strategies. Notably, Janus Henderson has been involved in several key transactions within the pharmaceuticals sector, including a $64 million Series D investment in Galecto, participation in a $100 million Series D financing for FORMA Therapeutics aimed at advancing treatments for sickle cell disease, and a $137 million Series B financing for VelosBio, which focuses on developing antibody-drug conjugates. Additionally, they participated in a $102 million Series C financing for Kymera Therapeutics and a $270 million Series A investment in BioNTech, highlighting their active role in supporting innovative pharmaceutical companies.

13. GV (Google Ventures)

• Website: gv.com
• Type: Venture Capital
• Headquarters: San Francisco Bay Area, California, United States (USA)
• Founded year: 2009
• Headcount: 51-200
• Number of deals in 2024: 74
• LinkedIn: gv

GV (Google Ventures) is a venture capital firm based in the San Francisco Bay Area, founded in 2009, with over $10 billion in assets under management. The firm provides funding and support to innovative technology startups across various sectors, including life sciences and artificial intelligence. Notably, GV has participated in significant funding rounds for pharmaceutical companies such as Forty Seven, which raised $75 million in Series B financing to develop an antibody against CD47, and Rani Therapeutics, which has raised multiple rounds of funding to advance its RaniPill technology for drug delivery. These transactions highlight GV's active role in supporting the development of groundbreaking therapies in the pharmaceuticals sector.

14. Casdin Capital, LLC

• Website: casdincapital.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 2012
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn: casdin-capital-llc

Casdin Capital, LLC is a New York-based venture capital firm founded in 2012, specializing in the life sciences sector. The firm focuses on investing in healthcare, biotechnology, synthetic biology, and technology, providing funding and strategic partnerships to innovative companies. Notably, Casdin Capital has been involved in several significant transactions in the pharmaceuticals context, including a $70 million Series D financing for CytomX Therapeutics, which is advancing Probody therapeutics, and participation in multiple funding rounds for Blueprint Medicines, a company focused on genomically defined product candidates. Additionally, they contributed to a $60 million Series B financing for Voyager Therapeutics and a $102 million Series A for Gritstone bio, both of which are engaged in developing novel therapeutics. These transactions highlight Casdin Capital's active role in supporting the advancement of pharmaceutical research and development.

15. F-Prime

• Website: fprimecapital.com
• Type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Founded year: 1946
• Headcount: 11-50
• Number of deals in 2024: 39
• LinkedIn: f-prime-capital-partners

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, founded in 1946. The firm specializes in creating and investing in healthcare and technology companies, providing both venture capital investments and advisory services to entrepreneurs. F-Prime has a global presence and expertise that enables them to effectively support start-ups in developing innovative solutions. Notably, F-Prime has participated in significant funding rounds for pharmaceutical companies, including Tetraphase Pharmaceuticals, where they were involved in Series A, B, and C funding rounds totaling over $70 million, aimed at advancing novel antibiotics into clinical studies. Additionally, they invested in Ironwood Pharmaceuticals during its Series C round, further showcasing their active role in the pharmaceuticals sector. Their portfolio also includes Aclaris Therapeutics, which raised $40 million in a Series C round, highlighting their ongoing commitment to the pharmaceutical industry.

16. Redmile Group

• Website: redmilegroup.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2007
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn: redmile-group

Redmile Group is an investment management firm based in San Francisco, California, founded in 2007. The firm specializes in providing asset management and investment strategies to high-net-worth individuals and institutional investors. With a focus on the financial services sector, Redmile Group has made significant investments in the pharmaceuticals industry, participating in key funding rounds for companies such as CytomX Therapeutics, which raised $70 million in a Series D financing round, and Blueprint Medicines, which secured $50 million in Series C funding. Additionally, they invested in Aurinia Pharmaceuticals during a Post-IPO equity round, contributing to the company's growth. More recently, Redmile Group was involved in a $215 million Series D funding round for Atea Pharmaceuticals, which is developing a COVID-19 drug. These transactions highlight Redmile Group's commitment to advancing pharmaceutical innovations and their active role in the sector.

17. Rock Springs Capital

• Website: rockspringscapital.com
• Type: Venture Capital
• Headquarters: Baltimore, Maryland, United States (USA)
• Founded year: 2013
• Headcount: 51-200
• Number of deals in 2024: 16
• LinkedIn: knectit

Rock Springs Capital is a venture capital investment firm based in Baltimore, Maryland, founded in 2013. The firm specializes in investment management and related financial services, catering to clients seeking asset management solutions. Rock Springs Capital has been involved in several notable transactions within the pharmaceuticals industry, including an $80 million post-IPO equity investment in Bristol-Myers Squibb in 2017, a $97 million Series B investment in BeiGene in 2015, and a $42 million Series B investment in Cidara Therapeutics in 2015. They also participated in a $30 million Series C funding for Zai Lab in 2017 and a $47 million Series C investment in G1 Therapeutics in 2016. These transactions highlight their active role in supporting innovative pharmaceutical companies and their commitment to the sector.

18. Polaris Partners

• Website: polarispartners.com
• Type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 19
• LinkedIn: polaris-partners

Polaris Partners is a venture capital firm based in Boston, Massachusetts, founded in 1996. The firm specializes in healthcare and biotechnology investments, partnering with entrepreneurs to provide funding and strategic guidance to help them innovate and grow their businesses. Polaris has a diverse portfolio that includes several companies focused on transformative healthcare solutions. Notably, they have been involved in significant transactions within the pharmaceuticals sector, such as multiple funding rounds for Acceleron Pharma, which raised over $100 million across several rounds, and Ironwood Pharmaceuticals, which secured $25 million in a venture round. Additionally, they invested in TARIS Biomedical, further emphasizing their active role in the pharmaceutical industry. Polaris operates primarily in the investment management space, supporting early-stage companies in bringing their products to market.

19. Silicon Valley Bank

• Website: svb.com
• Type: Venture Capital
• Headquarters: Santa Clara, California, United States (USA)
• Founded year: 1983
• Headcount: 5001-10000
• Number of deals in 2024: 31
• LinkedIn: silicon-valley-bank

Silicon Valley Bank is a commercial bank founded in 1983, located in Santa Clara, California, that specializes in providing financial services to the innovation economy, particularly tech startups and venture capital firms. They offer a range of products including business banking, global payments, and asset management, helping clients navigate financial challenges and support their growth. In the pharmaceuticals sector, Silicon Valley Bank has been involved in several significant transactions, providing debt financing to companies such as Reata Pharmaceuticals, which raised $35 million in 2017, and CymaBay Therapeutics, which secured $5 million in 2013. They also supported Pharming Group with $16.9 million in debt financing in 2015, and Aclaris Therapeutics with an $11 million term loan facility in 2020. Additionally, they provided an $80 million term loan to Exelixis in 2010, showcasing their active role in financing pharmaceutical companies and contributing to their growth.

Pharmaceuticals Insights: Key Investors in the US

Want to find more investors focusing on the pharmaceuticals industry?

With Inven, you'll also get to know:

• Deal History: Number of deals and their sizes.
• Portfolio: Companies they've invested in.
• Contact data: Key dealmakers, including their emails and phonenumbers.
• ...and much more!